{"id":647887,"date":"2023-04-18T19:52:01","date_gmt":"2023-04-18T19:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=647887"},"modified":"2023-04-18T19:52:01","modified_gmt":"2023-04-18T19:52:01","slug":"geographic-atrophy-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-ionis-roche-ngm-biopharma-apellis-pharma-novartis-genentech","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/geographic-atrophy-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-ionis-roche-ngm-biopharma-apellis-pharma-novartis-genentech_647887.html","title":{"rendered":"Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech"},"content":{"rendered":"
\n
\"Geographic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Geographic Atrophy Market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies in the market.<\/div>\n

Some of the major pharma and biotech companies such as Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Gyroscope Therapeutics,<\/strong> and others are actively working in the Geographic Atrophy Market.<\/em><\/p>\n

DelveInsight’s “Geographic Atrophy Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Geographic Atrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Geographic Atrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Geographic<\/p>\n

Geographic Atrophy: An Overview<\/strong><\/p>\n

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration, also called age-related macular degeneration (AMD or ARMD), is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet.” According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.<\/p>\n

Geographic Atrophy is a progressive, irreversible, and blinding disease affecting both eyes. Nearly two-thirds of geographic atrophy cases are reported in people 80 and older. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.<\/p>\n

Geographic Atrophy Market Key Facts<\/strong><\/p>\n